TY - JOUR
T1 - Effect of nalfurafine hydrochloride in cirrhotic patients with refractory pruritus
AU - Kawabe, Naoto
AU - Hashimoto, Senju
AU - Murao, Michihito
AU - Nakano, Takuji
AU - Kan, Toshiki
AU - Nakaoka, Kazunori
AU - Ohki, Masashi
AU - Ochi, Yuka
AU - Takamura, Tomoki
AU - Kurashita, Takamitsu
AU - Nomura, Sayuri
AU - Koyama, Keiji
AU - Fukui, Aiko
AU - Yoshioka, Kentaro
N1 - Publisher Copyright:
© 2017 The Japan Society of Hepatology.
PY - 2017
Y1 - 2017
N2 - We analyzed the characteristics of 671 patients with cirrhosis treated in our department between April 2014 and March 2016, and evaluated the therapeutic effects of nalfurafine hydrochloride in cirrhotic patients with refractory pruritus. Eighty-six patients (12.8%) of cirrhotic patients received oral antiallergic agents. Visual analog scale (VAS) scores significantly decreased, and the numbers of the patients with grade 2 or greater severity of pruritus in Kawashima’s criteria significantly decreased in 25 patients who were compared VAS and Kawashima’s criteria between baseline and 1-3 months after administration of nalfurafine. Nalfurafine was evaluated as effective in 18 patients (72.0%) by VAS scores, and AST levels tended to be higher in ineffective patients compared with effective patients. These results suggest that nalfurafine is expected to be effective in cirrhotic patients with refractory pruritus.
AB - We analyzed the characteristics of 671 patients with cirrhosis treated in our department between April 2014 and March 2016, and evaluated the therapeutic effects of nalfurafine hydrochloride in cirrhotic patients with refractory pruritus. Eighty-six patients (12.8%) of cirrhotic patients received oral antiallergic agents. Visual analog scale (VAS) scores significantly decreased, and the numbers of the patients with grade 2 or greater severity of pruritus in Kawashima’s criteria significantly decreased in 25 patients who were compared VAS and Kawashima’s criteria between baseline and 1-3 months after administration of nalfurafine. Nalfurafine was evaluated as effective in 18 patients (72.0%) by VAS scores, and AST levels tended to be higher in ineffective patients compared with effective patients. These results suggest that nalfurafine is expected to be effective in cirrhotic patients with refractory pruritus.
UR - http://www.scopus.com/inward/record.url?scp=85039765631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039765631&partnerID=8YFLogxK
U2 - 10.2957/kanzo.58.674
DO - 10.2957/kanzo.58.674
M3 - Article
AN - SCOPUS:85039765631
SN - 0451-4203
VL - 58
SP - 674
EP - 677
JO - Kanzo/Acta Hepatologica Japonica
JF - Kanzo/Acta Hepatologica Japonica
IS - 12
ER -